SCHEMBL23705673

SCHEMBL23705673

CC(C)(C)OC(=O)N1CCCC(c2csc(N)n2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 2/20 0.46
USP30 Q70CQ3 2/20 0.46
HPGDS O60760 1/20 0.43
ALOX5AP P20292 2/20 0.43
FEN1 P39748 2/20 0.43
PRMT5 O14744 1/20 0.43
BACE1 P56817 2/20 0.43
CTSD P07339 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PARP1 P09874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23705628 0.87 AXL (0.40) TRPV3MAPTKDM4EHSD17B10
SCHEMBL3060679 0.87 KDM4E (0.48) TRPV3USP30ALDH1A1MEN1MAPT
SCHEMBL23705061 0.81 GLS (0.47) TRPV3HPGDSALOX5APFEN1PRMT5
SCHEMBL25515493 0.81 GLS (0.47) TRPV3HPGDSALOX5APFEN1PRMT5
SCHEMBL25515491 0.81 GLS (0.47) TRPV3HPGDSALOX5APFEN1PRMT5
SCHEMBL8240664 0.81 SCN4A (0.45) USP30ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL356138 0.81 SCN4A (0.45) USP30ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL8215613 0.81 SCN4A (0.45) USP30ALDH1A1MEN1KMT2AHSD17B10
SCHEMBL2279416 0.81 KDM4E (0.48) TRPV3USP30HPGDSALDH1A1MEN1
SCHEMBL9962296 0.79 TRPV3 (0.53) TRPV3USP30HPGDSALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335373-B Compounds and uses thereof 福宏治疗公司 2025-05-20 CN disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
EP-4097096-A2 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
CN-115335373-A Compound and use thereof 福宏治疗公司 2022-11-11 CN disclosed
WO-2021155321-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348452-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 TRPV3 4589/4885USP30 2316/4885HPGDS 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.